Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 12Genitourinary 9Plasma cell 6Other hematologic neoplasm 5Thoracic 2Sarcoma 2Myeloid 2Gastrointestinal 2Dermatologic 2Head & Neck 1Gynecologic 1CNS 1Breast 1

Conditions

Melanoma 778Carcinoma, Non-Small-Cell Lung 198Lymphoma, T-Cell, Cutaneous 171Carcinoma, Renal Cell 139Neoplasms 130Mycosis Fungoides 120Breast Neoplasms 114Lymphoma, Large B-Cell, Diffuse 112Colorectal Neoplasms 111Lymphoma, Non-Hodgkin 110Sezary Syndrome 109Lymphoma, Follicular 107Neoplasm Metastasis 105Lymphoma 103Leukemia, Lymphocytic, Chronic, B-Cell 103Lymphoma, Mantle-Cell 100Lymphoma, B-Cell, Marginal Zone 98Hodgkin Disease 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Burkitt Lymphoma 94Squamous Cell Carcinoma of Head and Neck 92Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Large-Cell, Immunoblastic 86Lymphoma, Large-Cell, Anaplastic 86Ovarian Neoplasms 84Lung Neoplasms 80Immunoblastic Lymphadenopathy 79Sarcoma 67Pancreatic Neoplasms 65Head and Neck Neoplasms 64

Interventions

veliparib 1ripretinib 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Renal Insufficiency × Dermatologic × Clear all
NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Active not recruiting
94 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡